Cancer drug prices are set for a major reset as NPPA caps trade margin at 30% on 137 medicines from November 9.
Category: pharma
Trade Margins on Cancer Drugs: A Clear Review of Changes
Trade margins on cancer drugs are set to be capped by the Centre, prompting a broader price review.
Drug Prices: The Real Cost of Medications Explained
Drug prices are a major concern for many. Discover the real factors affecting medication costs in this insightful article.
Access to medicines: What are the real challenges?
Access to medicines is restricted by sanctions and regulations. What can be done?
Wellness Portfolio Acquisition: Proven Benefits for Jagsonpal
Wellness Portfolio Acquisition is a strategic move by Jagsonpal Pharmaceuticals, enhancing their market presence.
FDA Decision Watch: Key Approvals and Outcomes Ahead
FDA decision watch reveals crucial approvals for BMY, EGTX, and more.
South Korea Dry Eye Market: Best Proven Treatments Available
South Korea dry eye market is evolving with the approval of a third homegrown drug, offering new options for patients.
Korea Dry Eye Drug Approval: Worst Impact on GL PharmTech Shares
Korea dry eye drug approval has failed to boost GL PharmTech shares, raising concerns in the pharma market.
MHRA Approval Nottingham: Proven Benefits for Upperton
MHRA approval Nottingham is a significant milestone for Upperton’s sterile manufacturing site, enhancing their capabilities.
Pancreatic cancer drug access: The real struggle for patients
Pancreatic cancer drug access remains a major hurdle for patients seeking treatment.